Use of Cigarette and Maras Powder In Our İschemic Stroke Patients
Abstract
Keywords
References
- Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics- 2015 update: A report from the American Heart Association. Circulation 2015; 131:29-322. [CrossRef]
- Albertson M, Sharma J. Stroke: current concepts. S D Med, 2014;67:455, 457-61, 463-5.
- Boehme AK, Esenwa C, Elkind MS. Stroke risk factors, genetics, and prevention. Circulation research, 2017; 120: 472-95. [CrossRef]
- Glover ED, Glover PN. The smokeless tobacco problem: risk groups in North America. Pounds (millions), 1992;3.
- Aral M, Ekerbicer HC, Celik M, Ciragil P, Gul M. Comparison of Effects of Smoking and Smokeless Tobacco ‘Maras Powder’ Use on Humoral Immune System Parameters. Mediators Inflamm. 2006;2006:85019. [CrossRef]
- Kamal SM, Islam MA, Rahman MA. Sociopsychological Correlates of Smoking Among Male University Students in Bangladesh. Asia Pac J. Public Healt. 2011; 23:555–67. [CrossRef]
- Bonita R, Douglas K, Winkelmann R, De Courten M. The WHO STEP wise approach to surveillance (STEPS) of noncommunicable disease riskfactors. Chapter in (eds) McQueen, DV andPuska, P (editors); Global Risk Factor Surveillance. London: Kluwer Academic/Plenum Publishers; New York 2003; 9-22.
- Filippi A, Bignamini AA, Sessa E, Samani F, Mazzaglia G. Secondaryprevention of stroke in Italy. A Cross-sectionalsurvey in familypractice. Stroke 2003;34:1010-4. [CrossRef]
Details
Primary Language
English
Subjects
-
Journal Section
-
Authors
Yılmaz İnanç
Yusuf İnanç
Songül Bavli
Publication Date
June 1, 2020
Submission Date
-
Acceptance Date
-
Published in Issue
Year 2020 Number: 2